A Sysmex Group Company

CytoCell

Instructions For Use

REF: LPH 087-S / LPH 087

CLL *Plus* Screening Panel

CE IVD

PROFESSIONAL USE ONLY

www.cytocell.com

Further information and other languages available at www.ogt.com

Limitations

This device is designed to genomic losses gains rearrangements with breakpoints in the regions bounded by the red and green clones in this probe set, which includes the 13q14.3, *ATM*, *P53 (TP53)* and *MYB* regions and the chromosome 12 centromere. Genomic losses and gains outside of these regions, or partial losses and gains within these regions, may not be detected with this product.
The test is not intended for: use as a stand-alone diagnostic, prenatal testing, population-based screening, near-patient testing or self-testing. This product is intended for laboratory professional use only; all results should be interpreted by suitably-qualified staff, taking into account other relevant test results.
This product has not been validated for use on sample types or disease types other than those specified in the intended use.
Reporting and interpretation of FISH results should be consistent with professional standards of practice and should take into consideration other clinical and diagnostic information. This kit is intended as an adjunct to other diagnostic laboratory tests and therapeutic action should not be initiated on the basis of the FISH result alone.
Failure to adhere to the protocol may affect the performance and lead to false positive/negative results.
This kit has not been validated for purposes outside of the intended use stated.

Intended Use

The CytoCell CLL *Plus* Screening Panel is a qualitative, non-automated, fluorescence *in situ* hybridization (FISH) test used to detect chromosomal deletions in the 11q22.3 region on chromosome 11, the 17p13.1 region on chromosome 17 or the 13q14.2-q14.3 region on chromosome 13 and/or gains of the centromeric region on chromosome 12 and/or deletions involving the MYB region on chromosome 6 at location 6q23.3 in Carnoy's solution (3:1 methanol/acetic acid) fixed haematologically-derived cell suspensions from patients with chronic lymphocytic leukaemia (CLL).

Indications

This product is designed as an adjunct to other clinical and histopathological tests in recognised diagnostic and clinical care pathways, where knowledge of P53 (TP53), ATM deletion or D13S319 deletion status and/or gain of chromosome 12 centromere status would be important for clinical management.

Principles of the Test

Fluorescence *in situ* hybridisation (FISH) is a technique that allows DNA sequences to be detected on metaphase chromosomes or in interphase nuclei from fixed cytogenetic samples. The technique uses DNA probes that hybridise to entire chromosomes or single unique sequences, and serves as a powerful adjunct to G-banded cytogenetic analysis. This technique can now be applied as an essential investigative tool within prenatal, haematological and solid tumour chromosomal analysis. Target DNA, after fixation and denaturation, is available for annealing to a similarly denatured, fluorescently labelled DNA probe, which has a complementary sequence. Following hybridisation, unbound and non-specifically bound DNA probe is removed and the DNA is counterstained for visualisation. Fluorescence microscopy then allows the visualisation of the hybridised probe on the target material.

Probe Information

A selection of haematology probes and an alpha-satellite probe for chronic lymphocytic leukaemia (CLL).

Alpha Satellite 12 Plus for CLL

Trisomy 12 is a recurrent abnormality in CLL, seen in 20% of cases[1] and often appears as the unique cytogenetic aberration (40-60% of cases with trisomy 12)[2]. Patients with trisomy 12 are classified as low-risk in the absence of any other genetic lesions[3]. This product is also available in 5 (LPH 069-S) and 10 (LPH 069) test kit sizes and has been optimised for overnight hybridisation.

13q14.3

Deletions affecting 13q14 are the most frequent structural genetic aberrations in CLL[3,4,5]. This region is found to be heterozygously deleted in 30-60% and homozygously deleted in 10-20% of CLL patients[6]. Patients with 13q14 deletions are classified as very low risk, in the absence of any other genetic lesions[3].

P53 (TP53) (17p13.1)

The TP53 (*tumor protein p53*) gene at 17p13.1 is one of most important tumour suppressor genes; it acts as a potent transcription factor with fundamental role in the maintenance of genetic stability. Loss of TP53 is reported in 10% of patients with CLL, and is considered to be the poorest prognostic marker[3,7].

ATM (11q22.3)

The ATM (*ATM serine/threonine kinase*) gene at 11q22.3 is an important checkpoint gene involved in the management of cell damage and its function is to assess the level of DNA damage in the cell and attempt repair by phosphorylating key substrates involved in the DNA damage response pathway[8]. Loss of ATM is reported in 18% of patients with CLL, and is considered a poor prognostic marker in CLL[9].

MYB (6q23.3)

Deletions of chromosome 6q are recurrent in CLL. The MYB (*MYB proto-oncogene, transcription factor*) gene is essential in haematopoietic cell proliferation and differentiation[10,11]. It is located in band 6q23.3 and is provided as a marker for 6q deletion.

Probe Specification

13q14.3 Deletion Probe

13q14.2-q14.3, Red
13qter, 13q34, Green



The 13q14.2-q14.3 probes, labelled in red, cover the D13S319 and D13S25 markers. The 13qter sub-telomere specific probe (clone 163C9), labelled in green, allows identification of chromosome 13 and acts as a control probe.

ATM Deletion Probe

ATM, 11q22.3, Red
D11Z1, 11p11.1-q11.1, Green

CMP-H006 v005.00



The ATM probe is 182kb, labelled in red, and covers the telomeric end of the NPAT gene and the centromeric end of the ATM gene to just beyond the D11S3347 marker. The probe mix also contains a control probe for the 11 centromere (D11Z1) labelled in green.

Alpha Satellite 12 Plus for CLL
D12Z3, 12p11.1-q11.1, Red

The Alpha-Satellite 12 Plus Probe is a repeat sequence probe, labelled in red, which recognizes the centromeric repeat sequence D12Z3.

P53 (TP53) Deletion Probe
P53, 17p13 Red
D17Z1, 17p11.1-q11.1, Green

CMP-H039 V007.00



The p53 (TP53) probe is 161kb, labelled in red that covers the whole p53 (TP53) gene and the flanking regions. The probe mix also contains a control probe for the 17 centromere (D17Z1) labelled in green.

MYB Deletion Probe
MYB, 6q23.3, Red
D6Z1, 6p11.1-q11.1, Green



The MYB probe mix consists of a 185kb probe, labelled in red that covers the entire MYB gene and a telomeric region to this gene that includes a centromeric part of the AHI1 gene. This probe mix also contains a control probe for the 6 centromere (D6Z1) labelled in green.

Materials Provided
Probes*:* 50µl per vial (5 tests) or 100µl per vial (10 tests)
The probes are provided premixed in hybridisation solution (formamide; dextran sulphate; saline-sodium citrate (SSC)) and are ready to use.

Counterstain: 150µl per vial (15 tests)
The counterstain is DAPI antifade (ES: 0.125µg/ml DAPI (4,6-diamidino-2-phenylindole)).

Warnings and Precautions
1. For *in vitro* diagnostic use. For professional use only.
2. Wear gloves when handling DNA probes and DAPI counterstain.
3. Probe mixtures contain formamide, which is a teratogen; do not breathe fumes or allow skin contact. Handle with care; wear gloves and a lab coat.
4. DAPI is a potential carcinogen. Handle with care; wear gloves and a lab coat.
5. Dispose of all hazardous materials according to your institution's guidelines for hazardous waste disposal.
6. Operators must be capable of distinguishing the colours red, blue and green
7. Failure to adhere to the outlined protocol and reagents may affect the performance and lead to false positive/negative results.
8. The probe should not be diluted or mixed with other probes.
9. Failure to use 10µl of probe during the pre-denaturation stage of the protocol may affect the performance and lead to false positive/negative results.

Storage and Handling



The kit should be stored between -25ºC to -15ºC in a freezer until the expiry date indicated on the kit label. The probe and counterstain vials must be stored in the dark.

The probe remains stable throughout the freeze-thaw cycles experienced during normal use (where one cycle constitutes the probe's removal from and replacement into the freezer) and is photostable for up to 48 hours after being exposed to continuous lighting conditions. All efforts must be made to limit exposure to light and temperature changes.

Equipment and Materials Necessary but not Supplied
Calibrated equipment must be used:
1. Hotplate (with a solid plate and accurate temperature control up to 80ºC)
2. Calibrated variable volume micropipettes and tips range 1µl - 200µl
3. Water bath with accurate temperature control at 37ºC and 72ºC
4. Microcentrifuge tubes (0.5ml)
5. Fluorescence microscope (Please see Fluorescence Microscope Recommendation section)
6. Phase contrast microscope
7. Clean plastic, ceramic or heat-resistant glass Coplin jars
8. Forceps
9. Calibrated pH meter (or pH indicator strips capable of measuring pH 6.5 – 8.0)
10. Humidified container
11. Fluorescence grade microscope lens immersion oil
12. Bench top centrifuge
13. Microscope slides
14. 24x24mm coverslips
15. Timer
16. 37ºC incubator
17. Rubber solution glue
18. Vortex mixer
19. Graduated cylinders
20. Magnetic stirrer
21. Calibrated thermometer

Optional Equipment not Supplied
1. Cytogenetic drying chamber

Reagents Needed but not Supplied
1. 20x saline-sodium citrate (SSC) Solution
2. 100% Ethanol
3. Tween-20
4. 1M Sodium hydroxide (NaOH)
5. 1M Hydrochloric acid (HCl)
6. Purified water

Fluorescence Microscope Recommendation
Use a 100-watt mercury lamp or equivalent and oil immersion plan apochromat objectives 60/63x or 100x for optimal visualisation. The fluorophores used in this probe set will excite and emit at the following wavelengths:

Fluorophore	$Excitation_{max}$ [nm]	$Emission_{max}$ [nm]
Green	495	521
Red	596	615

Ensure appropriate excitation and emission filters that cover the wavelengths listed above are fitted to the microscope. Use a triple bandpass DAPI/green spectrum/red spectrum filter or a dual bandpass green spectrum/red spectrum filter for optimal simultaneous visualisation of the green and red fluorophores.

Check the fluorescence microscope before use to ensure it is operating correctly. Use immersion oil that is suitable for fluorescence microscopy and formulated for low autofluorescence. Avoid mixing DAPI antifade with microscope immersion oil as this will obscure signals. Follow manufacturers' recommendations in regards to the life of the lamp and the age of the filters.

Sample Preparation
The kit is designed for use on haematologically-derived cell suspensions fixed in Carnoy's solution (3:1 methanol/acetic acid) fixative, that are prepared according to the laboratory or institution guidelines. Prepare air dried samples on microscope slides according to standard cytogenetic procedures. The AGT *Cytogenetics Laboratory Manual* contains recommendations for specimen collection, culturing, harvesting and for slide making[12].

Solution Preparation
Ethanol Solutions
Dilute 100% ethanol with purified water using the following ratios and mix thoroughly:

- 70% Ethanol - 7 parts 100% ethanol to 3 parts purified water
- 85% Ethanol - 8.5 parts 100% ethanol to 1.5 parts purified water

Store the solutions for up to 6 months at room temperature in an airtight container.

2xSSC Solution

Dilute 1 part 20xSSC Solution with 9 parts purified water and mix thoroughly. Check pH and adjust to pH 7.0 using NaOH or HCl as required. Store the solution for up to 4 weeks at room temperature in an airtight container.

0.4xSSC Solution

Dilute 1 part 20xSSC Solution with 49 parts purified water and mix thoroughly. Check pH and adjust to pH 7.0 using NaOH or HCl as required. Store the solution for up to 4 weeks at room temperature in an airtight container.

2xSSC, 0.05% Tween-20 Solution

Dilute 1 part 20xSSC Solution with 9 parts purified water. Add 5µl of Tween-20 per 10ml and mix thoroughly. Check pH and adjust to pH 7.0 using NaOH or HCl as required. Store the solution for up to 4 weeks at room temperature in an airtight container.

FISH Protocol

(Note: Ensure that exposure of the probe and counterstain to laboratory lights is limited at all times).

Slide preparation

1. Spot the cell sample onto a glass microscope slide. Allow to dry. (**Optional, if using a cytogenetic drying chamber**: slides should be spotted using a cytogenetic drying chamber. The chamber should be operated at approximately 25°C and 50% humidity for optimal cell sample spotting. If a cytogenetic drying chamber is not available, use a fume hood as an alternative).
2. Immerse the slide in 2xSSC for 2 minutes at room temperature (RT) without agitation.
3. Dehydrate in an ethanol series (70%, 85% and 100%), each for 2 minutes at RT.
4. Allow to dry.

Pre-Denaturation

5. Remove the probe from the freezer and allow it to warm to RT. Briefly centrifuge tubes before use.
6. Ensure that the probe solution is uniformly mixed with a pipette.
7. Remove 10µl of probe per test, and transfer it to a microcentrifuge tube. Quickly return the remaining probe to the freezer.
8. Place the probe and the sample slide to prewarm on a 37ºC (+/- 1ºC) hotplate for 5 minutes.
9. Spot 10µl of probe mixture onto the cell sample and carefully apply a coverslip. Seal with rubber solution glue and allow the glue to dry completely.

Denaturation

10. Denature the sample and probe simultaneously by heating the slide on a hotplate at 75ºC (+/- 1ºC) for 2 minutes.

Hybridisation

11. Place the slide in a humid, lightproof container at 37ºC (+/- 1ºC) overnight.

Post-Hybridisation Washes

12. Remove the DAPI from the freezer and allow it to warm to RT.
13. Remove the coverslip and all traces of glue carefully.
14. Immerse the slide in 0.4xSSC (pH 7.0) at 72ºC (+/- 1ºC) for 2 minutes without agitation.
15. Drain the slide and immerse it in 2xSSC, 0.05% Tween-20 at RT (pH 7.0) for 30 seconds without agitation.
16. Drain the slide and apply 10µl of DAPI antifade onto each sample.
17. Cover with a coverslip, remove any bubbles and allow the colour to develop in the dark for 10 minutes.
18. View with a fluorescence microscope. (See **Fluorescence Microscope Recommendation**.)

Stability of Finished Slides

Finished slides remain analysable for up to 1 month if stored in the dark at/or below RT.

Procedural Recommendations

1. Baking or ageing of slides may reduce signal fluorescence
2. Hybridisation conditions may be adversely affected by the use of reagents other than those provided or recommended by Cytocell Ltd
3. Use a calibrated thermometer for measuring temperatures of solutions, waterbaths and incubators as these temperatures are critical for optimum product performance.
4. The wash concentrations, pH and temperatures are important as low stringency can result in non-specific binding of the probe and too high stringency can result in a lack of signal
5. Incomplete denaturation can result in lack of signal and over denaturation can also result in non-specific binding
6. Over hybridisation can result in additional or unexpected signals
7. Users should optimise the protocol for their own samples prior to using the test for diagnostic purposes
8. Suboptimal conditions may result in non-specific binding that may be misinterpreted as a probe signal

Interpretation of Results

Assessing Slide Quality

The slide should not be analysed if:

- Signals are too weak to analyse in single filters - in order to proceed with analysis, signals should appear bright, distinct and easily evaluable
- There are high numbers of clumped/overlapping cells obstructing the analysis
- >50% of the cells are not hybridised
- There is excess of fluorescent particles between cells and/or a fluorescent haze that interferes with the signals - in optimal slides the background should appear dark or black and clean
- Cell nucleus borders cannot be distinguished and are not intact

Analysis Guidelines

- Two analysts should analyse and interpret each sample. Any discrepancies should be resolved by assessment by a third analyst
- Each analyst should be suitably qualified according to recognised national standards
- Each analyst should score independently 100 nuclei for each sample. The first analyst should start the analysis from the left side of the slide and the second analyst from the right one
- Each analyst should document their results in separate sheets
- Analyse only intact nuclei, not overlapped or crowded nuclei or nuclei covered by cytoplasmic debris or high degree of autofluorescence
- Avoid areas where there is excess of cytoplasmic debris or non-specific hybridisation
- Signal intensity may vary, even with a single nucleus. In such cases, use single filters and/or adjust the focal plane
- In suboptimal conditions signals may appear diffuse. If two signals of the same colour touch each other, or the distance between them is no greater than two signal widths, or when there is a faint strand connecting the two signals, count as one signal
- If in doubt about whether a cell is analysable or not, then do not analyse it

Analysis Guidelines	
	Do not count – nuclei are too close together to determine boundaries
	Do not count overlapping nuclei – all areas of both nuclei are not visible
	Count as two red signals and two green signals – one of the two red signals is diffuse
	Count as two red signals and two green signals – the gap in one red signal is less than two signal widths

Expected Results

13q14.3 Deletion Probe

Expected Normal Signal Pattern



In a normal cell, two red and two green signals (2R, 2G) are expected.

Expected Abnormal Signal Patterns



In a cell with a hemizygous deletion of the 13q14.3, the expected signal pattern will be one red and two green signals (1R, 2G).



In a cell with a homozygous deletion, the expected signal pattern will be no red and two green signals (0R, 2G).

13q deletions in CLL are recognised as being heterogenous; small deletion within the 13q region may result in a small residual signal with this probeset.

Other signal patterns are possible in aneuploid/unbalanced specimens.

ATM Deletion Probe
Expected Normal Signal Pattern



In a normal cell, two red and two green signals (2R, 2G) are expected.

Expected Abnormal Signal Pattern



In a cell with an ATM deletion, the expected signal pattern will be one red and two green signals (1R, 2G).

Other signal patterns are possible in aneuploid/unbalanced specimens.

Alpha Satellite 12 Plus for CLL
Expected Normal Signal Pattern



In a normal cell, two red signals (2R) are expected.

Expected Abnormal Signal Pattern



In a cell with trisomy 12, the expected signal pattern will be three red signals (3R).

Other signal patterns are possible in aneuploid/unbalanced specimens.

P53 (TP53) Deletion Probe
Expected Normal Signal Pattern



In a normal cell, two red and two green signals (2R, 2G) are expected.

Expected Abnormal Signal Pattern



In a cell with a P53 deletion the expected signal pattern will be one red and two green signals (1R, 2G).
Other signal patterns are possible in aneuploid/unbalanced specimens.

MYB Deletion Probe
Expected Normal Signal Pattern



In a normal cell, two red and two green signals (2R, 2G) are expected.

Expected Abnormal Signal Pattern



In a cell with a MYB deletion, the expected signal pattern will be one red and two green signals (1R, 2G).

Other signal patterns are possible in aneuploid/unbalanced specimens.

Known Cross-Reactivity

Probe	Known Cross-reactivity
13q14.3 Deletion Probe	The green 13qter probe may show cross-hybridisation to the centromere of chromosome 19 and the p-arms of other chromosomes.
ATM Deletion Probe	The green D11Z1 probe may show up to 4 cross hybridisation signals to Xc and 17c.
Alpha Satellite 12 *Plus* for CLL	The probe may show red cross-hybridisation to 3c, 6c, 7c and 10c.
P53 (TP53) Deletion Probe	The green D17Z1 probe may show cross-hybridisation to the centromeres of chromosome 11 and X.
MYB Deletion Probe	No know cross-hybridisation

Adverse Event Reporting
If you believe this device has malfunctioned or suffered a deterioration in its performance characteristics which may have contributed to an adverse event (e.g. delayed or misdiagnosis, delayed or inappropriate treatment), this must be reported immediately to the manufacturer (**email:** vigilance@ogt.com).

If applicable, the event should also be reported to your national competent authority. A list of vigilance contact points can be found at: http://ec.europa.eu/growth/sectors/medical-devices/contacts/.

Specific Performance Characteristics
Analytical Specificity
Analytical specificity is the percentage of signals that hybridise to the correct locus and no other location. The analytical specificity was established by analysing a total of 200 target loci. The analytical specificity was calculated as the number of FISH signals that hybridised to the correct locus divided by the total number of FISH signals hybridised.

Table 1. Analytical Specificity for the CLL *Plus* Screening Panel

Kit	Probe	Target Locus	No. of Signals Hybridised to the Correct Locus	Total No. of Signals Hybridised	Specificity (%)
13q14.3 Deletion Probe	Red 13q14.3	13q14.3	200	200	100
	Green 13qter	13qter, 13q34	200	200	100
ATM Deletion Probe	Red ATM	11q22.3	200	200	100
	Green D11Z1	11q11.1-q11.1	200	200	100
Alpha Satellite 12 *Plus* for CLL	D12Z3 Red	12p11.1-q11.1	200	200	100
P53 (TP53) Deletion Probe	Red P53	17p13.1	200	200	100
	Green D17Z1	17p11.1-q11.1	200	200	100
MYB Deletion Probe	Red MYB	6q23	200	200	100
	Green D6Z1	6p11.1-q11.1	200	200	100

Analytical Sensitivity
Analytical sensitivity is the percentage of scoreable interphase cells with the expected normal signal pattern. The analytical sensitivity was established by analysing interphase cells across different normal samples. The sensitivity was calculated as the percentage of scoreable cells with the expected signal pattern (with a 95% confidence interval).

Table 2. Analytical Sensitivity for the CLL *Plus* Screening Panel

Kit	No. of Cells with Expected Signal Patterns	No. of Cells with Scoreable Signals	Sensitivity (%)	95% Confidence Interval
13q14.3 Deletion Probe	481	500	96.2	1.6
ATM Deletion Probe	482	500	96.4	1.0
Alpha Satellite 12 *Plus* for CLL	487	500	97.4	1.0
P53 (TP53) Deletion Probe	471	500	94.2	2.7
MYB Deletion Probe	479	500	95.8	1.7

Characterisation of Normal Cut-off Values
The normal cut-off value, in association with FISH probes, is the maximum percentage of scoreable interphase cells with a specific abnormal signal pattern at which a sample is considered normal for that signal pattern.

The normal cut-off value was established using samples from normal and positive patients. For each sample, the signal patterns of 100 cells were recorded. The Youden index was calculated to find the threshold value for which Sensitivity + Specificity-1 is maximised.

Table 3. Characterisation of Normal Cut-off Values for the CLL *Plus* Screening Panel

Kit	Abnormal signal pattern	Youden Index	Normal Cut-off (%)
13q14.3 Deletion Probe	1R, 2G or 0R, 2G	0.95	7
ATM Deletion Probe	1R, 2G	0.99	9
Alpha Satellite 12 *Plus* for CLL	3R	0.99	3
P53 (TP53) Deletion Probe	1R, 2G	0.90	10
MYB Deletion Probe	1R, 2G	0.97	8

Laboratories must verify cut-off values using their own data[13, 14].

Precision and Reproducibility
Precision is a measure of the natural variation of a test when repeated several times under the same conditions. This was assessed by analysing repeats of the same lot number of probe tested on the same sample, in the same conditions on the same day.

Reproducibility is a measure of the variability of a test and has been established in terms of sample-to-sample, day-to-day and batch-to-batch variability. Day-to-day reproducibility was assessed by analysing the same samples on three different days. Batch-to-batch reproducibility was assessed by analysing the same samples using three different lot numbers of probe on one day. Sample-to-sample reproducibility was assessed by analysing three replicates of a sample on one day. For each sample, signal patterns of 100 interphase cells were recorded and the percentage of cells with the expected signal pattern was calculated.

The reproducibility and precision were calculated as the Standard Deviation (STDEV) between replicates for each variable and overall mean STDEV.

Table 4. Reproducibility and Precision for the CLL *Plus* Screening Panel

Variable	Standard Deviation (STDEV)				
	13q14.3 Deletion Probe	ATM Deletion Probe	Alpha Satellite 12 *Plus* for CLL	P53 (TP53) Deletion Probe	MYB Deletion Probe
Precision	0.72	0.38	0.72	2.63	1.09
Sample-to-sample	0.58	0.38	0.89	2.30	1.19
Day-to-day	0.96	0.58	0.51	2.39	1.20
Batch-to-batch	1.40	1.27	1.27	1.68	0.90
Overall deviation	1.03	1.01	1.15	2.16	1.06

Clinical Performance
The clinical performance was established on a representative sample of the intended population for the product. For each sample, the signal patterns of ≥100 interphase cells were recorded. A normal/abnormal determination was made by comparing the percentage of cells with the specific abnormal signal pattern to the normal cut-off value. The results were then compared to the known status of the sample.

The results of the clinical data were analysed in order to produce sensitivity, specificity and cut off values using a one-dimensional approach.

Table 5. Clinical Performance for the CLL *Plus* Screening Panel

Probe	Clinical Sensitivity (true positive rate, TPR)	Clinical Specificity (true negative rate, TNR)	False Positive rate (FPR) = 1 – Specificity
13q14.3 Deletion Probe	96.3%	99.1%	0.9%
ATM Deletion Probe	100%	99.2%	0.8%
Alpha Satellite 12 *Plus* for CLL	100%	100%	0%
P53 (TP53) Deletion Probe	92.5%	97.1%	2.9%
MYB Deletion Probe	97.8%	99.6%	0.4%

Additional Information
For additional product information please contact the CytoCell Technical Support Department.
T: +44 (0)1223 294048
E: techsupport@cytocell.com
W: www.ogt.com

References

1. Swerdlow *et al.,* (eds,) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue, Lyon, France, 4th edition, IARC,2017
2. Puiggros et al., Biomed Res Int 2014;1-13
3. Rossi et al., Blood 2013;121(8):1403-1412
4. Juliusson G et al., N Eng J Med 1990;323:720-4
5. Kasar et al., Nature Communications 2015;6:1-12
6. Hammarsund M et al., FEBS Letters 2004;556:75-80
7. Baliakas P, et al., Leukemia. 2014;(April):1-8
8. Stankovic et al., Blood 2004;103(1):291-300
9. Dohner et al., N Eng J Med 2000;343:1910-1916
10. Clappier et al., Blood 2007;110(4):1251-1261
11. Stilgenbauer et al., Leukemia,1999;13:1331-1334
12. Arsham, MS., Barch, MJ. and Lawce HJ. (eds.) (2017) The *AGT Cytogenetics Laboratory Manual*. New Jersey: John Wiley & Sons Inc.
13. Mascarello JT, Hirsch B, Kearney HM, et al. Section E9 of the American College of Medical Genetics technical standards and guidelines: fluorescence in situ hybridization. Genet Med. 2011;13(7):667-675.
14. Wiktor AE, Dyke DLV, Stupca PJ, Ketterling RP, Thorland EC, Shearer BM, Fink SR, Stockero KJ, Majorowicz JR, Dewald GW. *Preclinical validation of fluorescence in situ hybridization assays for clinical practice*. Genetics in Medicine. 2006;8(1):16–23.

Guide to Symbols

REF	**en:** Catalogue number
IVD	**en:** *In vitro* diagnostic medical device
LOT	**en**: Batch code
	**en:** Consult instructions for use
	**en:** Manufacturer
	**en:** Use-by date
	**en:** Temperature limit
	**en:** Keep away from sunlight
	**en:** Contains sufficient for <n> tests
CONT	**en:** Contents

Patents and Trademarks
CytoCell is a registered trademark of Cytocell Ltd.

Cytocell Ltd.
Oxford Gene Technology,
418 Cambridge Science Park,
Milton Road,
Cambridge, CB4 0PZ, UK
T: +44(0)1223 294048
F: +44(0)1223 294986
E: probes@cytocell.com
W: www.ogt.com